
Eprazinone dihydrochloride
CAS No. 10402-53-6
Eprazinone dihydrochloride ( —— )
产品货号. M10205 CAS No. 10402-53-6
Eprazinone 2HClide 是一种具有溶解粘液、溶解分泌物和支气管解痉作用的化合物。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
50MG | ¥267 | 有现货 |
![]() ![]() |
100MG | ¥437 | 有现货 |
![]() ![]() |
500MG | ¥1401 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Eprazinone dihydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Eprazinone 2HClide 是一种具有溶解粘液、溶解分泌物和支气管解痉作用的化合物。
-
产品描述Eprazinone 2hydrochloride is a drug with proposed mucolytic, secretolytic, and bronchial antispasmodic properties.(In Vitro):Eprazinone specifically displaces binding to the NK1R. Although Eprazinone displays a rather weak inhibition of [125I]BH-SP binding to NK1R, at a concentration of 25 μM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity.(In Vivo):Eprazinone (50-200 mg/kg; oral gavage; daily; for 4 days; adult male rats) at a dose of 200 mg/kg significantly increases total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreases total neutral lipids. Lower doses of Eprazinone significantly decrease neutral lipid levels without affecting the phospholipids.In airway epithelial studies, mucosal addition of Eprazinone produces a dose-dependent partially reversible decrease in short-circuit current (Isc). The decrease in Isc at lower Eprazinone concentrations is accounted for entirely by a decrease in net chloride secretion while at higher concentrations both sodium and chloride transport are affected.
-
体外实验Eprazinone specifically displaces binding to the NK1R. Although Eprazinone displays a rather weak inhibition of [125I]BH-SP binding to NK1R, at a concentration of 25 μM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity.
-
体内实验Eprazinone (50-200 mg/kg; oral gavage; daily; for 4 days; adult male rats) at a dose of 200 mg/kg significantly increases total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreases total neutral lipids. Lower doses of Eprazinone significantly decrease neutral lipid levels without affecting the phospholipids.In airway epithelial studies, mucosal addition of Eprazinone produces a dose-dependent partially reversible decrease in short-circuit current (Isc). The decrease in Isc at lower Eprazinone concentrations is accounted for entirely by a decrease in net chloride secretion while at higher concentrations both sodium and chloride transport are affected. Animal Model:Adult male pathogen free Fischer 344 inbred rats (200-250 g) Dosage:50 mg/kg, 100 mg/kg, and 200 mg/kg Administration:Oral gavage; daily; for 4 days Result:At a dose of 200 mg/kg significantly increased total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreased total neutral lipids.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域Other Indications
-
适应症——
化学信息
-
CAS Number10402-53-6
-
分子量453.44
-
分子式C24H32N2O2·2HCl
-
纯度>98% (HPLC)
-
溶解度Water: 18 mg/mL (39.69 mM); DMSO: 1 mg/mL (2.2 mM)
-
SMILESCl.Cl.CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Thrall RS, et al. Exp Lung Res, 1992, 18(3), 409-420.
产品手册




关联产品
-
GRGDSPK 2TFA(111119-...
GRGDSPK 2TFA 是一种抑制肽,用于抑制 RGD 介导的整合素和细胞外基质分子之间的粘附。
-
AG-270
AG-270 是 MAT2A 的变构和口服活性抑制剂。
-
16-Oxoalisol A
16-Oxoalisol A is a natural product.